NCT07087977 HoYAG vs TFL in miniPCNL With ClearPetra
| NCT ID | NCT07087977 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Kansas Medical Center |
| Condition | Nephrolithiasis |
| Study Type | INTERVENTIONAL |
| Enrollment | 150 participants |
| Start Date | 2025-08-22 |
| Primary Completion | 2027-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 150 participants in total. It began in 2025-08-22 with a primary completion date of 2027-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Mini percutaneous nephrolithotripsy is the treatment of choice for kidney stones over 2cm. This procedure commonly uses laser energy for breaking the stones, and among possible laser platforms, Hoyag and thulium fiber laser are FDA approved. Recently, this procedure has also included the use of vacuum assisted renal access sheaths, which allows suction to be employed together with the breaking of stones. This study intends to compare outcomes when using either laser platforms with suction sheaths in participants undergoing mini percutaneous nephrolithotripsy for the treatment of kidney stones.
Eligibility Criteria
Inclusion Criteria: 1. Males or females over 18 years of age 2. Patients with kidney stones, with stone burden larger than 15 mm. 3. Patients undergoing new percutaneous access with primary, supine, unilateral mini-PCNL. Exclusion Criteria: 4. Simultaneous use of more than 1 laser platform or other form of fragmentation (e.g., ultrasonic). 5. Patients undergoing simultaneous treatment of contralateral kidney stones during the same procedure. 6. Patients undergoing simultaneous treatment of ureteral stones during the same procedure. 7. Pregnant patients. 8. Presence of genitourinary anatomical abnormalities. 9. Uncorrected coagulopathy. 10. External urinary catheters. 11. Immunosuppressed patients. 12. Non-elective procedures.
Contact & Investigator
Bristol Whiles, MD
PRINCIPAL INVESTIGATOR
University of Kansas Medical Center
Frequently Asked Questions
Who can join the NCT07087977 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Nephrolithiasis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07087977 currently recruiting?
Yes, NCT07087977 is actively recruiting participants. Contact the research team at jledesma2@kumc.edu for enrollment information.
Where is the NCT07087977 trial being conducted?
This trial is being conducted at Kansas City, United States.
Who is sponsoring the NCT07087977 clinical trial?
NCT07087977 is sponsored by University of Kansas Medical Center. The principal investigator is Bristol Whiles, MD at University of Kansas Medical Center. The trial plans to enroll 150 participants.